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Abstract 
Background and Aim: Gestational trophoblastic disease (GTD) is defined as a group of disorders; they are 
characterized by uncontrolled trophoblastic cell proliferation and overproduction of β-HCG. It seems that an 
inappropriate diet is one of the major risk factors of GTD. Regardless of the size of the uterus; mole depletion by 
curettage suction is usually the preferred treatment. This study aimed to evaluate the effect of vitamin A and 
curettage suction on the faster reduction of β-hCG level, and faster recovery of disease, consequently. Materials 
and Methods: In this study case (n=26) and control (n=26) groups received 50,000 IU of vitamin A 
intramuscularly, before and after curettage. β-hCG was measured weekly and after reaching zero every month for 
six months. RIA was used for measurement. Results: Vitamin A reduced the level of β-hCG to zero in the patient 
compared to the control, one week earlier; this effect was statistically significant (P-Value <0.05). One of the 
members of the control group during follow-up progressed to gestational trophoblastic disease (GTN). There was 
no significant relationship between ABO blood groups among the two groups (P-Value: 0.9). There was no 
significant relationship between gravity, parity and hematology parameters between the two groups (P-
Value >0.05). Conclusion: Finally, it can be said that vitamin A intake in patients with GTD, along with other 
therapies, can improve the speed of recovery; it can prevent the disease progression. However, it does not prevent 
progression to GTN, completely. Therefore, further studies are needed in future studies. 
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Introduction 
Gestational trophoblastic disease (GTD) is a group of 
disorders that comprises a range of tumors with 
different biological characteristics ranging from 
benign to malignant (1). GTD includes several groups 
such as hydatidiform mole, invasive mole, and 
choriocarcinoma; it is caused by the uncontrolled 
proliferation of trophoblast cells and impaired 
apoptosis (2). so far, many effective factors have been 
introduced which are involved in the pathogenesis of 
the gestational trophoblastic disease (GTN); however, 
the main factor has not been identified (3). Some of 
these risk factors are gestational age, previous mole 
history, β-hCG levels, and platelet count (4). patients 
diet has been introduced as an important factor in 
GTD development, recently. Therefore, people with a 
diet that lacks essential vitamins such as folate, E, and 
A, are more susceptible to GTD (5, 6). Among these, 
Vitamin A appears to play an important role in 
preventing cell proliferation and inducing apoptosis. 
Vitamin A induces apoptosis in cells by stimulating 
p53 activation; recent studies suggest that vitamin A 
intake can reduce the proliferation of malignant cells 
by inducing apoptosis, in some cancers (7). Thus, 
they declared that concomitant use of chemotherapy 
with vitamin A is associated with increased 
remission, in patients with high-risk GTD (8). In the 
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present study, we investigated the vitamin A effect on 
β-hCG reduction in patients with molar pregnancy 
after curettage. 
Methods 
Patients and control selection 
This study was performed on 52 patients with a 
history of molar pregnancy who referred to Firoozgar 
Hospital of Iran University of Medical Sciences 
during 2018-2019.  The inclusion criteria were as 
following: gestational age below 12 weeks, no history 
of the Underlying disease, β-hCG <100,000 IU, and 
complete mole; The exclusion criteria included β-
hCG > 100,000IU and incomplete mole. Evaluated 
variables included gravity, parity, patients age, 
hematological parameters, the β-hCG level before and 
after treatment, and blood group.  The studied patients 
were divided into two groups of A (n=26) and 
B(n=26). Group A members received 50000IU before 
and after curettage intramuscularly; Group B 
members did not receive any vitamin A, they just 
underwent curettage suction (figure.1). 
 
 
Figure.2. Evaluation of decreased β-hCG level in 
patient and control subjects 
The serum β-hCG level was measured by the 
radioimmune assay (RIA) method. Serum β-hCG 
levels were measured before the curettage suction and 
in the 4th, 7th, 14th, and 28th days after treatment. 
measuring process continued, until the weekly level 
of β-hCG achieve to zero; this β-hCG was compared 
with the levels before the treatment. After reaching 
zero, it was measured monthly for up to 6 months in 
both groups.  
Statistical analysis: Chi-square statistical method was 
used to measure nominal data; dependent and 
independent sample t-tests were done to measure 
quantitative data. Data were analyzed by SPSS 
software (version 23). P < 0.05 was considered 
statistically significant. 
Results 
The mean age was 30.00±6.22 in group A (case 
group), and 33.12±4.85 in group B (control group); 
age differences were not statistically significant 
between the two groups (P-Value: 0.25). 
 
Evaluation of hematological parameters in two 
groups 
After evaluating hematological parameters, higher 
levels of MCHC, PLCR, MPV, PDW, platelet, MCH, 
and hemoglobin were observed in the patients; 
whereas RDW, MCV, white and red blood cells were 
significantly higher in the control group. None of the 
findings were statistically significant (Table 1). 
 
The Relationship between β-hCG Levels in two 
groups 
The mean level of β-hCG was 
48392/08±24900.77 mIU/ml, before treatment and 
vitamin A intake, in the intervention group. It was 
26266/93±39394/31 mIU/ml in the control group, no 
significant relationships were observed between them 
(P-Value: 0.899).  
The mean β-hCG levels were measured in the 
intervention group in the 4th and 7th days after 
treatment, which were 3307.92±3052.12 mIU/ml and 
303.00±203.16 mIU/ml, respectively; these values 
were 6082.08±6714.46 mIU/ml and 1753.52±1356.69 
mIU/ml in the control group, respectively. These 
differences were statistically significant (P-Value: 
0.02 for day 4 and P-Value: 0.000 for day 7). The 
mean β-hCG level was 109.50±113.47 mIU/ml, 
22.46±30.79 mIU/ml and 0.00±0.00 mIU/ml in the 4th 
week after treatment in the intervention group 
respectively; these amounts were 
748.79±415.73 mIU/ml, 194.37±98.96 mIU/ml and 
49.85±29.73 mIU/ml in the control group, 
respectively. These differences were statistically 
significant (Table 2). 
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Table 1. Associated hematological parameters between patient and control subjects 
Variable Patients Control P-value 
MCHC 35.49± 2.01 34.88± 1.72 0.105 
PLCR 32.08± 7.29 27.92± 9.37 0.09 
MPV 10.67± 0.96 10.20± 1.14 0.231 
PDW 14.04± 1.80 13.44± 2.28 0.059 
RDW 13.21± 0.90 13.63± 1.02 0.112 
PLT 235.38± 73.18 235.31± 66.71 0.581 
MCH 31.34± 1.59 30.49± 1.74 0.668 
MCV 85.80± 3.52 87.00± 3.11 0.475 
HCT 35.25± 2.68 35.77± 3.37 0.162 
Hb 12.64± 0.95 12.62± 1.20 0.07 
RBC 4.00± 0.45 4.09± 0.46 0.937 
WBC 7.83± 2.35 7.94± 2.91 0.985 
Pariteh (Median, (Range)) 0 (0-3) 0 (0-2) 0.899 
Gravid (Median, (Range)) 1 (1-5) 1 (1-3) 0.902 
Data are expressed as mean ± SD (n=26 for patients and n=26 for control). P-value calculated by independent t test. 
Abbreviation: MCHC: mean corpuscular hemoglobin concentration; PLCR: Platelet larger cell ratio; MPV: mean platelet 
volume; PDW: Platelet distribution width; RDW: Red blood cell distribution width; PLT: Platelet; MCH: mean cell hemoglobin; 
MCV: Mean corpuscular volume; HCT: hematocrit; Hb: Hemoglobin ; RBC: Red blood cell; WBC: White blood cell.  
 
Table 2. Associated hematological parameters between patient and control personals 
Variable Patients(mIU/ml ) Control (mIU/mL) P-value 
β-hCG 1 48392.08± 24900.77 26266.93± 39394.31 0.899
* 
β-hCG 4 3307.92± 3052.12 6082.08± 6714.46 0.02
* 
β-hCG 7 303.00± 203.16 1753.52± 1356.69 0.000
* 
β-hCG 14 109.50± 113.47 748.79± 415.73 0.001
* 
β-hCG 21 22.46± 30.79 194.37± 98.96 0.015
* 

























Data are expressed as mean ± SD (n=26 for patients and n=26 for control) for BHCG. For ABO and RH blood group expressed 
as number (%).  *calculated by Mann-Whitney. ** calculated by chi-square.  
As shown, the intervention group had a faster rate of 
β-hCG reduction in comparison to the control group. 
The level of β-hCG was reduced to zero in the 
intervention group during the fourth week after 
treatment; it was 49.85±29.73 mIU/ml in the control 
group too. This finding emphasizes the effect of 
vitamin A on the accelerated reduction of the β-hCG 
level. 
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Evaluation of blood groups in two groups 
Results showed that all patients were Rh-positive, 
while in the control group, 96.2% had positive Rh-, 
and about 3.8% were negative. The frequency of 
groups A and O were higher in the patient's group, 
while the B and AB blood groups were more frequent 
in the controls; this difference was not statistically 
significant (P-Value: 0.23) (Table 2). 
Discussion 
Molar pregnancy is a disease characterized by 
overproduction of β-hCG by placental cells (9, 10); 
inherited and acquired factors affect the disease. 
Mutations in the apoptosis controller genes are one of 
the heredity factors and acquired including gestational 
age, previous molar, gravity, parity, and many others 
(11, 12). Recently, vitamin A is introduced as an 
effective factor in cell apoptosis; its use combined 
with chemotherapy drugs can prevent malignant cell 
proliferation (13, 14). Vitamin A is involved in many 
physiological processes such as differentiation, 
proliferation, and normal cell growth (15). In 
pathogenic conditions, it inhibits the proliferation of 
tumor cells by inducing apoptosis; it prevents 
metastasize to other parts of the body by inhibiting 
angiogenesis (16). Vitamin A inhibits cancer cell 
proliferation by regulating the function of 
transcription factors (17). This organic matter active 
the signaling pathways that inhibit the cell cycle and 
the cancer cells growth (7, 18). 
A study by Andri et al. was conducted to evaluate the 
role of vitamin A in preventing malignancy of molar 
pregnancy; the disease progression rate and 
malignancy were lower in vitamin A receiver in 
comparison with those who did not receive any 
vitamins. Also, this study evaluated some of the risk 
factors and their association with disease progression. 
The results showed that there were no significant 
relationships between the age of patients and the 
molar pregnancy incidence. Also, no significant 
relationships were observed between parity and the 
progression of disease and malignancy in both groups 
(7). In the study by Kolusari and associates the levels 
of vitamins A, E, and D were evaluated in patients 
with molar pregnancy; the results showed higher 
levels of vitamins in control individuals. They play 
the antioxidant role in the body and protect against 
the production of reactive oxygen species. No 
significant relationships were detected between 
gestational age, gravidity, and parity in patients and 
controls (6). The present study revealed no significant 
relationships between the ages of the patients treated 
with vitamin A and the control group (P-Value: 0.25). 
Also, it was found that there were no significant 
relationships between gravity and parity of both 
groups (P-Value: 0.90 for gravity and P-Value: 0.89 
for parity). Research by Shamshiri Milani et al. which 
investigated molar pregnancy risk factors revealed 
that the percentage of blood group A was higher in 
the control group compared to the patients (41.5% vs. 
59.5%). Other ABO blood groups were more frequent 
in the control group too; however, the frequency of A 
blood group was statistically significant (P-value: 
0.00) (19). In the present study, the frequency of 
different blood groups was not statistically significant 
(Table 2). 
A study by Bakhtyari et al. which evaluated the role 
of risk factors in the pathogenesis of molar pregnancy 
revealed that the level of β-hCG was higher in high-
risk molar patients. β-hCG reduces after treatment; it 
achieves to the control level. They concluded that β-
hCG levels could be used as a risk factor in the 
patient's follow-up; it is applicable after treatment, as 
well as before treatment to identify high-risk patients 
(20). In the present study, the level of β-hCG in the 
patient group reached zero faster; it prevented the 
progression of the disease. Also, statistical analysis 
showed that there was a significant difference 
between the two groups after vitamin A intake . 
The findings of research by Fatama et al. in 2015, 
state platelets count was higher in patients with molar 
pregnancy compared to controls. In contrast, the 
differences in WBC, PDW, and MPV were higher in 
the control group compared to patients; But this 
difference was only significant for platelets (P-Value: 
0.00) (21). In the present study, after evaluating 
clinical parameters between patients with molar 
pregnancy and controls, it was shown that there was 
no significant relationship between these parameters 
in the two groups.  
Conclusion 
Finally, according to the data obtained from this 
study, unlike other researches there was no significant 
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relationship between hematological parameters in two 
groups of individuals under study; our analysis 
revealed that hematological parameters cannot be 
considered as suitable prognostic factors. But the 
most important point observed in this study was the 
effect of vitamin A on preventing disease progression 
and accelerating the recovery of patients. vitamin A 
intake is suggested in the early stages of the disease 
and even as a prophylactic for those who are at the 
risk of molar pregnancy; it can prevent the 
progression into malignancy by reducing the 
production of β-hCG. 
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